The agreement between US-based Amyrise and Spain-based ADL Bionatur is the second part of an agreement that the two players implemented earlier on this year.
The agreement is a show of confidence in ADL Bionatur’s contract manufacturing capabilities and builds on the existing agreement, providing a clean, best-in-class fermentation process for ingredients use in the personal care, cosmetics, fragrance and wellness fields.
Further growth of customer base
The agreement gives Amyris a production footprint in Europe, but the ingredients are manufactured for a global client base.
“We are very pleased with the production quality and cost we’ve achieved and our ability to access sugarcane-based feedstock for our fermentation capacity at ADL in Spain,” said Eduardo Alvarez, Amyris CEO.
“This asset combined with our expanded access to the DSM-owned Brotas facility enables us the flexibility to meet growing demand from our customers. With a significant volume of ingredients produced at this site during the second half we can confirm no expected negative change to our gross margin target as a result of this expansión.”
Building with scope for future expansion
Both sides have also stated that, by expanding on their agreement, both business are eyeing further expansion to production the future, if demand continues.
"A clear recognition of the experience, capacity and technical knowledge of the company ADL Biopharma and the trust that Amyris has in us. Additionally, this exponential growth of our turnover associated with new contracts, demonstrates the behavior of the demand for these types of products in the market." said Pilar de la Huerta, CEO of ADL Bionatur. "It reinforces our sales targets for 2018, which we maintain at around double of our turnover in 2017. Currently, the company has already committed more than 85% of its fermentation capacity for the next two years for our customers."
